article thumbnail

Novartis looking into future of its Sandoz’ generics business

pharmaphorum

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.

article thumbnail

The critical role of the generics sector during the pandemic

pharmaphorum

“Now more than ever, it is our responsibility as a sector to ensure affordable access to healthcare and enable the future longevity of medicine development and supply.”. The generics medicines sector can, too, play a substantial part in discovering new areas for licensed products to be used in. Delivery of essential medicines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rebranded Servier eyes €3bn in cancer drug sales by 2030

pharmaphorum

The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.

article thumbnail

New report sets out clear steps pharma cos to curb AMR risk in antibiotic production

Express Pharma

The report analyses selected companies of varying sizes that manufacture and market antibiotics – including research-based pharma companies, generic medicine manufacturers and business-to-business providers. Despite progress, significant gaps remain.

article thumbnail

Koye Pharma allies with Sonde on vocal biomarkers for COPD

pharmaphorum

Koye sells generic medicines, including COPD therapies such as Spirodin (doxofylline) and Spirodin-Ax (doxofylline and ambroxol), used to reduce open the airways and reduce coughing in patients with the respiratory condition.

article thumbnail

Astellas loses bid to block Lexiscan generics in US

pharmaphorum

It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US.

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

In a bid to resolve both physical and financial restrictions inhibiting equitable access to quality medicines, the Jan Aushadhi scheme was launched in 2008 and envisaged the setting up of dedicated Janaushadhi Kendras to provide quality generic medicines at capped prices for the general public.